PARP inhibitors Dec 19, 2018 FDA Approves Myriad Genetics' BRACAnalysis CDx With Lynparza in Earlier Ovarian Cancer Setting Oct 16, 2018 FDA Approves Myriad Genetics BRCA CDx With Pfizer's Metastatic Breast Cancer Drug Oct 10, 2018 Myriad Upgraded to Overweight by Piper Jaffray; Signs Lab Service Deal with Pfizer Jul 11, 2017 After Securing CE-IVD for Debut Hereditary Cancer Dx, Korea's NGeneBio Readies NGS Tests for Launch Premium Mar 27, 2017 FDA Approves Myriad Genetics' BRACAnalysis as Complementary Dx for New PARP Inhibitor Dec 20, 2016 Foundation Medicine's Regulatory Win for NGS CDx Sets Precedent; Adoption Challenge Remains Premium Dec 19, 2016 Foundation BRCA CDx is First NGS Companion Test to Get FDA Nod Nov 2, 2016 Myriad Moving Ahead With PMA Filing for MyChoice HRD as Companion Test for Niraparib Premium Jul 6, 2016 Ovarian Cancer Study Provides Support for Myriad's HRD Test as CDx for Tesaro's Niraparib Premium Breaking News In Brief This Week: NIH, Thermo Fisher Scientific, Biocept, Castle Biosciences, Biodesix Biological Dynamics Taps Two Firms to Study Utility, Economics of Pancreatic Cancer Detection Test FDA Grants EUAs to Lucira Health Molecular COVID/Flu Test, Azure Biotech, CorDx COVID Antigen Tests Biocare Medical Acquires Empire Genomics Meridian Bioscience Fiscal Q4 Revenues Fall 14 Percent, Full-Year Revenues Grow 5 Percent Japanese Consortium Launches Study to Evaluate Utility of Blood-Based Alzheimer's Markers
